Please use this identifier to cite or link to this item: http://hdl.handle.net/11718/26008
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBranstetter, Lee
dc.contributor.authorChatterjee, Chirantan
dc.contributor.authorHiggins, Matthew J.
dc.date.accessioned2022-12-30T09:44:21Z
dc.date.available2022-12-30T09:44:21Z
dc.date.issued2022-12-01
dc.identifier.citationBranstetter, L., Chatterjee, C., & Higgins, M. J. (2022). Generic competition and the incentives for early-stage pharmaceutical innovation. Research Policy, 51(10), 104595. https://doi.org/10.1016/J.RESPOL.2022.104595en_US
dc.identifier.issn0048-7333
dc.identifier.urihttp://hdl.handle.net/11718/26008
dc.description.abstractWhat impact has rising generic competition had on the nature and direction of pharmaceutical innovation? We find broad-based, strong evidence that pharmaceutical companies have diverted their new drug development efforts away from therapeutic markets already well-served by generic drugs. We also find that increasing generic competition induces firms to shift their R&D activity toward more biologic-based products and away from chemical-based products. We conclude by discussing potential implications of our results for long-run innovation policy.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofResearch Policyen_US
dc.subjectPharmaceutical innovationen_US
dc.subjectGeneric entryen_US
dc.subjectNature of innovationen_US
dc.subjectInnovation policyen_US
dc.titleGeneric competition and the incentives for early-stage pharmaceutical innovationen_US
dc.typeArticleen_US
Appears in Collections:Journal Articles

Files in This Item:
File Description SizeFormat 
Generic_competition_and_the_incentives_for_early-stage_pharmaceutical_innovation.pdf
  Restricted Access
Generic_competition_and_the_incentives_for_early-stage_pharmaceutical_innovation729.04 kBAdobe PDFView/Open Request a copy


Items in IIMA Institutional Repository are protected by copyright, with all rights reserved, unless otherwise indicated.